Pangenotypic DAAs glecaprevir (formerly ABT-493; NS3/4A inhibitor developed by AbbVie and Enanta) and pibrentasvir (formerly ABT-530; NS5A inhibitor), comprise the interferon (IFN) - and ribavirin (RBV)-free regimen G/P. In seven phase 2/3 trials, G/P achieved SVR12 rates of 92-100% across all six major HCV genotypes (GTs). We present an integrated analysis from these studies on the efficacy of 8 and 12 weeks of G/P treatment in non-cirrhotic patients with GT1-6 infection.